TD Asset Management Inc Acquires New Shares in Immuneering Corporation $IMRX

TD Asset Management Inc purchased a new position in shares of Immuneering Corporation (NASDAQ:IMRX) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 145,180 shares of the company’s stock, valued at approximately $1,016,000. TD Asset Management Inc owned approximately 0.35% of Immuneering at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IMRX. Jane Street Group LLC bought a new position in shares of Immuneering during the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Immuneering in the third quarter valued at approximately $35,000. Future Financial Wealth Managment LLC bought a new position in shares of Immuneering in the third quarter valued at approximately $35,000. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering in the second quarter worth $47,000. Finally, XTX Topco Ltd bought a new stake in shares of Immuneering during the 2nd quarter worth $90,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IMRX. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Buying and Selling at Immuneering

In other news, Director Peter Feinberg acquired 20,000 shares of the company’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director owned 135,441 shares of the company’s stock, valued at $589,168.35. This trade represents a 17.32% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas J. Schall bought 21,645 shares of Immuneering stock in a transaction dated Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the purchase, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 51,819 shares of company stock worth $234,472. Company insiders own 22.90% of the company’s stock.

Immuneering Trading Down 3.7%

IMRX opened at $4.98 on Friday. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08. The stock has a market capitalization of $321.56 million, a PE ratio of -2.80 and a beta of 0.46. The firm has a 50-day moving average price of $5.25 and a two-hundred day moving average price of $6.07.

Immuneering Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.